Insights into Sars‐CoV‐2 vaccination in patients with chronic plaque psoriasis on systemic treatments

Gisondi, Paolo; Geat, Davide; Naldi, Luigi; Piaserico, Stefano

doi:10.1111/jdv.17200

Cited by 11 publications

(12 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, extensive reviews regarding this topic are available, and deduce a satisfactory safety profile with various biologicals [75]. For example, anti-IL-17 drugs are not expected to significantly impair the efficacy of COVID-19 vaccines based on experiences with influenza vaccines [76]. Interestingly, apremilast (a phosphodiesterase-4 inhibitor) has been associated with a low risk of flares of psoriasis, while at the same time enabling a sufficient vaccine immune response [77].…”

Section: Th17-polarized Cutaneous Inflammation 331 Psoriasis Vulgarismentioning

confidence: 99%

Cutaneous Adverse Reactions to COVID-19 Vaccines: Insights from an Immuno-Dermatological Perspective

et al. 2021

View full text Add to dashboard Cite

(1) Background: Numerous vaccines are under preclinical and clinical development for prevention of severe course and lethal outcome of coronavirus disease 2019 (COVID-19). In light of high efficacy rates and satisfactory safety profiles, some agents have already reached approval and are now distributed worldwide, with varying availability. Real-world data on cutaneous adverse drug reactions (ADRs) remain limited. (2) Methods: We performed a literature research concerning cutaneous ADRs to different COVID-19 vaccines, and incorporated our own experiences. (3) Results: Injection site reactions are the most frequent side effects arising from all vaccine types. Moreover, delayed cutaneous ADRs may occur after several days, either as a primary manifestation or as a flare of a pre-existing inflammatory dermatosis. Cutaneous ADRs may be divided according to their cytokine profile, based on the preponderance of specific T-cell subsets (i.e., Th1, Th2, Th17/22, Tregs). Specific cutaneous ADRs mimic immunogenic reactions to the natural infection with SARS-CoV-2, which is associated with an abundance of type I interferons. (4) Conclusions: Further studies are required in order to determine the best suitable vaccine type for individual groups of patients, including patients suffering from chronic inflammatory dermatoses.

show abstract

Section: Th17-polarized Cutaneous Inflammation 331 Psoriasis Vulgarismentioning

confidence: 99%

Cutaneous Adverse Reactions to COVID-19 Vaccines: Insights from an Immuno-Dermatological Perspective

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In the face of this pandemic, having some degree of immunity is better than having none. EADV task force on quality of life and patient‐oriented outcome recently advised psoriatic patients to receive COVID‐19 vaccine and those who had COVID‐19 infection to continue following health measures to protect themselves and others 12 …”

Section: Psoriasismentioning

confidence: 99%

COVID ‐19 vaccines: What dermatologists should know?

Ayatollahi

Hosseini

Firooz

et al. 2021

Dermatologic Therapy

View full text Add to dashboard Cite

As COVID‐19 vaccination has started worldwide to control this pandemic, dermatologists may face various challenges with these new vaccines. In this manuscript, we review different types of available COVID‐19 vaccines and their various production platforms. Vaccination considerations in patients with skin diseases, especially those using immunomodulatory drugs will be presented. Finally, adverse cutaneous reactions of COVID‐19 vaccines will be reviewed.

show abstract

“…Prior to the second vaccination, the patient was being treated with deucravacitinib as part of a clinical trial and was completely clear of lesions. Other authors have noted that while there is a theoretical possibility that immunosuppressive treatment may lead to a less effective immune response to the vaccine, a biological would need to be discontinued for several weeks during which time there would be a reasonable probability that there would be disease recurrence [9]. Thus, while there may be some doubts about the ability of an immunosuppressed patient to mount an optimal immunological response to COVID-19 vaccines, vaccination is nonetheless considered to provide some degree of protection against SARS-CoV-2 [9].…”

Section: Dear Editormentioning

confidence: 99%

“…Other authors have noted that while there is a theoretical possibility that immunosuppressive treatment may lead to a less effective immune response to the vaccine, a biological would need to be discontinued for several weeks during which time there would be a reasonable probability that there would be disease recurrence [9]. Thus, while there may be some doubts about the ability of an immunosuppressed patient to mount an optimal immunological response to COVID-19 vaccines, vaccination is nonetheless considered to provide some degree of protection against SARS-CoV-2 [9]. Indeed, both the National Psoriasis Foundation and the American College of Rheumatology have recommended that such patients receive COVID-19 vaccination, consistent with age restrictions, since the benefits outweigh the possible risk of a new-onset autoimmunity [10,11].…”

Section: Dear Editormentioning

confidence: 99%

Safety of COVID-19 vaccines in patients with psoriasis undergoing therapy with anti-interleukin agents

Talamonti

Galluzzo

2021

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

Introduction: There is very limited kn3e safety of COVID-19 vaccines in patients with psoriasis who are being treated with biological agents. We present our experience in 369 patients with moderate-to-severe psoriasis undergoing therapy with anti-IL agents who were vaccinated against SARS-CoV-2. Areas covered: None of the 369 patients referred to any serious adverse event related to vaccination against COVID-19, while about one-third reported mild adverse events similar to those seen in the general population that were resolved within 48 hours. No patient discontinued biological therapy to receive a COVID-19 vaccine. Expert opinion: Our observations provide evidence that COVID-19 vaccines can be considered safe in patients with moderate-to-severe psoriasis who are receiving anti-IL therapy.

show abstract

Insights into Sars‐CoV‐2 vaccination in patients with chronic plaque psoriasis on systemic treatments

Cited by 11 publications

References 9 publications

Cutaneous Adverse Reactions to COVID-19 Vaccines: Insights from an Immuno-Dermatological Perspective

Cutaneous Adverse Reactions to COVID-19 Vaccines: Insights from an Immuno-Dermatological Perspective

COVID ‐19 vaccines: What dermatologists should know?

Safety of COVID-19 vaccines in patients with psoriasis undergoing therapy with anti-interleukin agents

Contact Info

Product

Resources

About